Sourav Bachhar, Suryasarathi Kumar, Basudeb Dutta, Somnath Das
{"title":"Emerging horizons of AI in pharmaceutical research.","authors":"Sourav Bachhar, Suryasarathi Kumar, Basudeb Dutta, Somnath Das","doi":"10.1016/bs.apha.2025.01.016","DOIUrl":null,"url":null,"abstract":"<p><p>Artificial Intelligence (AI) has revolutionized drug discovery by enhancing data collection, integration, and predictive modeling across various critical stages. It aggregates vast biological and chemical data, including genomic information, protein structures, and chemical interactions with biological targets. Machine learning techniques and QSAR models are applied by AI to predict compound behaviors and predict potential drug candidates. Docking simulations predict drug-protein interactions, while virtual screening eliminates large chemical databases through efficient sifting. Similarly, AI supports de novo drug design by generating novel molecules, optimized against a particular biological target, using generative models such as generative adversarial network (GAN), always finding lead compounds with the most desirable pharmacological properties. AI used in clinical trials improves efficiency by pinpointing responsive patient cohorts leveraging genetic profiles and biomarkers and maintaining propriety such as dataset diversity and compliance with regulations. This chapter aimed to summarize and analyze the mechanism of AI to accelerate drug discovery by streamlining different processes that enable informed decisions and bring potential life-saving therapies to market faster, amounting to a breakthrough in pharmaceutical research and development.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"103 ","pages":"325-348"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.apha.2025.01.016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Emerging horizons of AI in pharmaceutical research.
Artificial Intelligence (AI) has revolutionized drug discovery by enhancing data collection, integration, and predictive modeling across various critical stages. It aggregates vast biological and chemical data, including genomic information, protein structures, and chemical interactions with biological targets. Machine learning techniques and QSAR models are applied by AI to predict compound behaviors and predict potential drug candidates. Docking simulations predict drug-protein interactions, while virtual screening eliminates large chemical databases through efficient sifting. Similarly, AI supports de novo drug design by generating novel molecules, optimized against a particular biological target, using generative models such as generative adversarial network (GAN), always finding lead compounds with the most desirable pharmacological properties. AI used in clinical trials improves efficiency by pinpointing responsive patient cohorts leveraging genetic profiles and biomarkers and maintaining propriety such as dataset diversity and compliance with regulations. This chapter aimed to summarize and analyze the mechanism of AI to accelerate drug discovery by streamlining different processes that enable informed decisions and bring potential life-saving therapies to market faster, amounting to a breakthrough in pharmaceutical research and development.